- Lobbying
- Lobbying by Ovarian Cancer Research Fund Alliance
Lobbying Relationship
Bills mentioned
H.RES.811: Expressing support for the designation of September 2016 as National...
Sponsor: Rosa DeLauro (D-Conn.)
S.RES.521: A resolution expressing support for the designation of September 2016 as...
Sponsor: Kelly Ayotte (R-N.H.)
S.1566: Cancer Drug Coverage Parity Act of 2015
Sponsor: Mark Steven Kirk (R-Ill.)
H.R.2739: Cancer Drug Coverage Parity Act of 2015
Sponsor: Leonard Lance (R-N.J.)
S.2566: Sexual Assault Survivors' Rights Act
Sponsor: Jeanne Shaheen (D-N.H.)
H.R.1409: Cancer Drug Parity Act of 2017
Sponsor: Leonard Lance (R-N.J.)
H.R.1625: Consolidated Appropriations Act, 2018
Sponsor: Edward Royce (R-Calif.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jeremy Scott | Senator Mike DeWine- Legislative Correspondent, Staff Assistant, Intern |
Ilisa Halpern Paul | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. House of Representatives
Centers For Disease Control & Prevention (CDC)
U.S. Senate
U.S. House of Representatives
U.S. Senate
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate